Banerjee Subhashis sold $16K of ARTV

Banerjee Subhashis (Chief Medical Officer) sold 4,037 shares of Artiva Biotherapeutics, Inc. (ARTV) at $3.91 on 2026-11-17.

Original reporting
SEC EDGAR · Banerjee Subhashis
Published Nov 18, 2026, 9:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
high confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The filing provides transparency on insider selling activity by the Chief Medical Officer, but it does not include any new clinical, regulatory, or financial guidance.

02

Market read

Traders may note the insider sale for sentiment, but the transaction value is small and does not constitute a fundamental catalyst.

03

What to watch

Insider sales can be driven by diversification, taxes, or personal liquidity needs; without additional context, traders should avoid extrapolating to business performance.

Relevance 3/10Novelty 3/10Timing: filed after-hours on 2026-11-18, reflecting the 2026-11-17 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Artiva Biotherapeutics, Inc.

Company-level read

Ticker impact

$ARTVNeutralHigh confidence
Context

Artiva Biotherapeutics CMO Banerjee Subhashis sold 4,037 shares in an open-market transaction for about $15.8k, per a fresh SEC Form 4.

Expected impact

Likely limited downside pressure or no reaction as the transaction size is small and lacks a stated catalyst.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure, but the dollar value (~$15.8k) is modest and does not indicate a company-specific operational or financial change.

Market effects

Minimal, as the disclosure is company-specific insider activity with no sector-wide signal.

None expected.

None expected.

Counterpoint

The absence of a cited 10b5-1 plan could be interpreted as discretionary selling, but the small size makes it unlikely to be information-bearing.

Key entities

  • Artiva Biotherapeutics, Inc.

    US-listed biotech subject of the Form 4 insider sale disclosure.

  • Banerjee Subhashis

    Chief Medical Officer who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.